Andrea Loaiza-Perez

Dr. Andrea Loaiza-Perez


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Cancer Letters
Verified
Journal Article
Closed access
EBEileen Brantley
Eileen Brantley
MCMariana A. Callero
Mariana A. Callero
DBDamian E. Berardi
Damian E. Berardi
PCPetreena Campbell
Petreena Campbell
LRLeah Rowland
Leah Rowland
USUbaldo Soto
Ubaldo Soto

Verified
Journal Article
Open access
PDF file
BIBoris Itkin
Boris Itkin
ABAlastair Breen
Alastair Breen
LTLyudmila Turyanska
Lyudmila Turyanska
ESEduardo Omar Sandes
Eduardo Omar Sandes
TBTracey Bradshaw
Tracey Bradshaw
ALAndrea Loaiza-Perez
Andrea Loaiza-Perez
Kidney cancer rapidly acquires resistance to antiangiogenic agents, such as sunitinib, developing an aggressive migratory phenotype (facilitated by c-Metsignal transduction). The Aryl hydrocarbon receptor (AhR) has recently been postulated as a molecular target for cancer treatment. Currently, there are two antitumor agent AhR ligands, with activity against renal cancer, that have been tested clinically: aminoflavone (AFP 464, NSC710464) and the benzothiazole (5F 203) prodrug Phortress. Our studies investigated the action of AFP 464, the aminoflavone pro-drug currently used in clinical trials, and 5F 203 on renal cancer cells, specifically examining their effects on cell cycle progression, apoptosis and cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 potently inhibited the migration of TK-10, Caki-1 and SN12C cells as well as the migration signal transduction cascade, involving c-Met signaling, in TK-10 cells. Current investigations are focused on the development of nano-delivery vehicles, apoferritin-encapsulated benzothiazoles 5F 203 and GW610, for the treatment of renal cancer. These compounds have shown improved antitumor effects against TK-10 cells in vitro at lower concentrations compared with a naked agent.

12 June 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
GLGabriela A. Luzzani
Gabriela A. Luzzani
MCMariana A. Callero
Mariana A. Callero
AKAnchala I. Kuruppu
Anchala I. Kuruppu
VTValentina Trapani
Valentina Trapani
CFCarolina Flumian
Carolina Flumian
ALAndrea Loaiza-Perez
Andrea Loaiza-Perez

5 April 2012 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
ALAndrea Loaiza-Perez
Andrea Loaiza-Perez
MCMariana A. Callero
Mariana A. Callero
GSGuadalupe V. Suárez
Guadalupe V. Suárez
GLGabriela Luzzani
Gabriela Luzzani
BIBoris Itkin
Boris Itkin
BNBinh Nguyen
Binh Nguyen
Aminoflavone (AF; NSC 686288, AFP464, NSC710464) is a new anticancer drug that has recently entered phase II clinical trials. It has demonstrated antiproliferative effects in MCF-7 human breast cancer cells mediated by the aryl hydrocarbon receptor (AhR). AF also exhibits noteworthy evidence of antitumor activity in vitro and in vivo against neoplastic cells of renal origin. AF treatment of sensitive renal cells, in contrast to resistant cells, promotes the induction of CYP1A1, the covalent binding of AF-reactive intermediates and apoptosis. Based on this evidence, the aim of this study was to evaluate the role of AhR, the main transcriptional regulator of CYP1A1, in the antiproliferative effects of AF in human renal cancer cells. AF-cytoxicity in human renal cell lines and a renal cancer cell strain was assessed by MTS assay in the presence or absence of an Ahr inhibitor. Drug-induced AhR nuclear translocation was evaluated by western blotting of AhR in cytosolic and nuclear fractions and by measuring xenobiotic response element-driven luciferase activity. Apoptosis induced by the drug was evaluated by 4,6-diamidino-2-phenylindole and acridine orange/ethidium bromide staining and by measuring phosphorylated P53 (p-P53) and P21 levels, caspase 3 activation and poly(ADP-ribose) polymerase cleavage. AF inhibited cell growth in a dose-dependent manner in TK-10, Caki-1, SN12-C and A498 human renal cells but not in ACHN cells. The antiproliferative effect of AF was abrogated by pre-incubation of TK-10, Caki-1 and SN12-C cells with the AhR antagonist, α-naphthoflavone. AF treatment also induced apoptosis in TK-10, Caki-1 and SN12-C cells, which was not observed in ACHN cells. AF induced time-dependent AhR nuclear translocation and AhR transcriptional activity in sensitive renal cancer cell lines. A renal cell strain derived from a human papillary tumor also showed sensitivity to AF, as well as AhR pathway activation and drug-induced apoptosis. AhR translocation could be included as a marker of sensitivity to AF in sensitive renal tumor cells of different histological origin, in ongoing phase II clinical trials.

1 March 2021 in Cancer Letters
Verified
Journal Article
Closed access
Nicole Ursula R. MavingireNicole Ursula R. Mavingire
Nicole Ursula R. Mavingire
PCPetreena Campbell
Petreena Campbell
JWJonathan Wooten
Jonathan Wooten
JAJoyce Amarachi Aja
Joyce Amarachi Aja
MDMelissa Davis
Melissa Davis
EBEileen Brantley
Eileen Brantley

27 April 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MCMariana A. Callero
Mariana A. Callero
CRCristina E. Rodriguez
Cristina E. Rodriguez
ASAldana Sólimo
Aldana Sólimo
EJElisa Bal de Kier Joffé
Elisa Bal de Kier Joffé
ALAndrea Loaiza-Perez
Andrea Loaiza-Perez